Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $221,247.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 12,090 shares of Travere Therapeutics stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $18.30, for a total value of $221,247.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. This represents a 18.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Travere Therapeutics Stock Performance

Travere Therapeutics stock traded down $0.07 during mid-day trading on Monday, reaching $18.18. The company had a trading volume of 983,459 shares, compared to its average volume of 1,397,194. The company has a 50 day moving average of $16.85 and a 200-day moving average of $11.52. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $20.33. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -4.00 and a beta of 0.70.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same period in the previous year, the company posted ($1.17) earnings per share. The company’s quarterly revenue was up 69.6% compared to the same quarter last year. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -3.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently bought and sold shares of the business. EntryPoint Capital LLC bought a new position in shares of Travere Therapeutics during the 1st quarter worth about $32,000. CWM LLC lifted its stake in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares during the period. Quarry LP acquired a new stake in Travere Therapeutics during the third quarter valued at approximately $105,000. Diversified Trust Co bought a new stake in shares of Travere Therapeutics in the 3rd quarter valued at approximately $161,000. Finally, DRW Securities LLC acquired a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $95,000.

Analysts Set New Price Targets

Several research firms have commented on TVTX. Citigroup decreased their target price on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th. Bank of America increased their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. HC Wainwright reduced their target price on Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating for the company in a report on Friday, September 27th. Finally, Piper Sandler increased their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.62.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.